Brokers Issue Forecasts for Teva Pharmaceutical Industries Ltd’s Q1 2019 Earnings (TEVA)

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) – Oppenheimer cut their Q1 2019 EPS estimates for shares of Teva Pharmaceutical Industries in a research report issued on Sunday, February 10th. Oppenheimer analyst E. Rajavelu now forecasts that the company will post earnings of $0.73 per share for the quarter, down from their previous estimate of $0.75. Oppenheimer currently has a “Hold” rating on the stock. Oppenheimer also issued estimates for Teva Pharmaceutical Industries’ Q2 2019 earnings at $0.60 EPS.

Several other analysts have also recently commented on the stock. UBS Group upgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating in a research note on Wednesday, January 23rd. Bank of America upgraded shares of Teva Pharmaceutical Industries from an “underperform” rating to a “buy” rating and set a $16.12 price objective for the company in a research note on Thursday, January 3rd. Piper Jaffray Companies upgraded shares of Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and raised their price objective for the company from $15.00 to $16.00 in a research note on Wednesday, January 23rd. Morgan Stanley upgraded shares of Teva Pharmaceutical Industries from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $20.00 to $27.00 in a research note on Monday, November 5th. Finally, Zacks Investment Research cut shares of Teva Pharmaceutical Industries from a “hold” rating to a “strong sell” rating in a research note on Monday, January 21st. Three research analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $22.98.

Shares of NYSE TEVA opened at $18.82 on Tuesday. The company has a quick ratio of 0.61, a current ratio of 0.94 and a debt-to-equity ratio of 1.75. Teva Pharmaceutical Industries has a 52 week low of $14.59 and a 52 week high of $25.96. The stock has a market capitalization of $18.53 billion, a P/E ratio of 4.79, a P/E/G ratio of 5.83 and a beta of 1.46.

In other Teva Pharmaceutical Industries news, VP Hafrun Fridriksdottir sold 1,643 shares of the firm’s stock in a transaction dated Wednesday, January 2nd. The shares were sold at an average price of $15.70, for a total transaction of $25,795.10. Following the completion of the transaction, the vice president now directly owns 13,469 shares in the company, valued at approximately $211,463.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.43% of the company’s stock.

A number of large investors have recently bought and sold shares of the business. Northstar Group Inc. grew its holdings in shares of Teva Pharmaceutical Industries by 34.9% during the fourth quarter. Northstar Group Inc. now owns 15,468 shares of the company’s stock worth $239,000 after buying an additional 4,000 shares in the last quarter. Cacti Asset Management LLC grew its holdings in shares of Teva Pharmaceutical Industries by 12.5% during the fourth quarter. Cacti Asset Management LLC now owns 577,904 shares of the company’s stock worth $8,911,000 after buying an additional 64,180 shares in the last quarter. Virtu Financial LLC grew its holdings in shares of Teva Pharmaceutical Industries by 665.0% during the third quarter. Virtu Financial LLC now owns 271,537 shares of the company’s stock worth $5,849,000 after buying an additional 236,044 shares in the last quarter. Handelsbanken Fonder AB purchased a new stake in shares of Teva Pharmaceutical Industries during the third quarter worth about $485,000. Finally, Korea Investment CORP grew its holdings in shares of Teva Pharmaceutical Industries by 9.5% during the third quarter. Korea Investment CORP now owns 605,633 shares of the company’s stock worth $13,045,000 after buying an additional 52,600 shares in the last quarter. Hedge funds and other institutional investors own 62.11% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Featured Article: What are retained earnings?

Earnings History and Estimates for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply